ERBB2 and breast carcinoma: In fact, THP followed by AC became a care standard for neoadjuvant therapy in HER2+ breast cancer during its assessment in I-SPY2, with the FDA approval of pertuzumab based on results from multiple neoadjuvant trials7,9,10.